Submitted by Anonymous (not verified) on 16 October 2026 - 14:00
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 12, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 12, Status: Authorised